Bielack Stefan S, Kager Leo, Kühne Thomas, Langer Thorsten, Reichardt Peter, Blattmann Claudia, Kevric Matthias, Mettmann Vanessa, Sorg Benjamin, Hecker-Nolting Stefanie
Cooperative Osteosarcoma Study Group, Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women's Medicine, Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, 70174 Stuttgart, Germany.
Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, 48149 Münster, Germany.
Cancers (Basel). 2023 Feb 28;15(5):1520. doi: 10.3390/cancers15051520.
Osteosarcoma treatment has benefitted greatly from collaborative research. This paper describes the history and accomplishments of the Cooperative Osteosarcoma Study Group (COSS), mainly dedicated to clinical questions, as well as remaining challenges.
Narrative review of over four decades of uninterrupted collaboration within the multi-national German-Austrian-Swiss COSS group.
Since its very first prospective osteosarcoma trial starting in 1977, COSS has continuously been able to provide high-level evidence on various tumor- and treatment-related questions. This includes both the cohort of patients enrolled into prospective trials as well as those patients excluded from them for various reasons, followed in a prospective registry. Well over one hundred disease-related publications attest to the group's impact on the field. Despite these accomplishments, challenging problems remain.
Collaborative research within a multi-national study group resulted in better definitions of important aspects of the most common bone tumor, osteosarcoma, and its treatments. Important challenges continue to persist.
骨肉瘤治疗因合作研究而受益匪浅。本文描述了骨肉瘤协作研究组(COSS)的历史与成就,该研究组主要致力于临床问题以及尚存的挑战。
对德国 - 奥地利 - 瑞士跨国COSS组四十多年来不间断的合作进行叙述性综述。
自1977年开展首个前瞻性骨肉瘤试验以来,COSS一直能够就各种肿瘤及治疗相关问题提供高水平证据。这包括纳入前瞻性试验的患者队列以及因各种原因被排除在外但在前瞻性登记处随访的患者。一百多篇与疾病相关的出版物证明了该研究组对该领域的影响。尽管取得了这些成就,但仍存在具有挑战性的问题。
多国研究组内的合作研究对最常见骨肿瘤骨肉瘤及其治疗的重要方面进行了更好的定义。重要挑战依然存在。